
Medpace Holdings (MEDP) Stock Forecast & Price Target
Medpace Holdings (MEDP) Analyst Ratings
Bulls say
Medpace Holdings is in a strong position thanks to its efficient operations, diversified revenue streams, and a well-established presence in the growing biotechnology, pharmaceutical, and medical device sectors. With a strong backlog and a robust pipeline, the company is well-positioned for future growth. Risks to consider include potential government funding delays and the possibility of not delivering clinical trials on time, but overall the company's fundamentals are solid and could support continued bookin
Bears say
Medpace Holdings is a full-service contract research organization with a high reliance on biopharma funding, presenting risks if funding dries up. Government shutdowns and volatility could also impact Medpace's ability to generate revenue. Additionally, the company's reliance on a few large metabolic programs presents a revenue risk in 2027 once those programs roll off. Despite improving bookings and commercial KPIs, Medpace may face margin pressure and uncertainty about competitive dynamics in the CRO space, causing downside risks to its shares.
This aggregate rating is based on analysts' research of Medpace Holdings and is not a guaranteed prediction by Public.com or investment advice.
Medpace Holdings (MEDP) Analyst Forecast & Price Prediction
Start investing in Medpace Holdings (MEDP)
Order type
Buy in
Order amount
Est. shares
0 shares